Skip to main content Accessibility help
×
Home

Response to Prior and Fitzpatrick

  • Sirisha Kundrapu (a1), Venkata Sunkesula (a1), Myreen Tomas (a1) (a2) and Curtis J. Donskey (a1) (a2)
  • In response to commentaries on:

Abstract

  • An abstract is not available for this content so a preview has been provided below. Please use the Get access link above for information on how to access this content.

Copyright

Corresponding author

Address correspondence to Curtis J. Donskey, MD, Geriatric Research, Education, and Clinical Center, Cleveland Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, Ohio 44106 (curtisd123@yahoo.com).

References

Hide All
1. Kundrapu, S, Sunkesula, V, Tomas, M, Donskey, CJ. Skin and environmental contamination in patients diagnosed with Clostridium difficile infection but not meeting clinical criteria for testing. Infect Control Hosp Epidemiol 2015;36:13481350.
2. Koo, HL, Van, JN, Zhao, M, et al. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol 2014;35:667673.
3. Polage, CR, Gyorke, CE, Kennedy, MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015;175:17921801.
4. Buckel, WR, Avdic, E, Carroll, KC, Gunaseelan, V, Hadhazy, E, Cosgrove, SE. Gut check: Clostridium difficile testing and treatment in the molecular testing era. Infect Control Hosp Epidemiol 2015;36:217221.
5. Peterson, LR, Robicsek, A. Does my patient have Clostridium difficile infection? Ann Intern Med 2009;151:176179.
6. Planche, T, Wilcox, MH. Diagnostic pitfalls in Clostridium difficile infection. Infect Dis Clin North Am 2015;29:6382.
7. Prior, AR, Fitzpatrick, F. Clostridium difficile—To Test or Not to Test? Response to Kundrapu et al. Infect Control Hosp Epidemiol 2016;37:361362.
8. Biswas, JS, Patel, A, Otter, JA, van Kleef, E, Goldenberg, SD. Contamination of the hospital environment from potential Clostridium difficile excretors without active infection. Infect Control Hosp Epidemiol 2015;36:975977.
9. Kyne, L, Warny, M, Qamar, A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390397.
10. Louie, TJ, Cannon, K, Byrne, B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012;55(Suppl 2):S132S142.
11. Donskey, CJ, Kundrapu, S, Deshpande, A. Colonization versus carriage of Clostridium difficile . Infect Dis Clin North Am 2015;29:1328.

Response to Prior and Fitzpatrick

  • Sirisha Kundrapu (a1), Venkata Sunkesula (a1), Myreen Tomas (a1) (a2) and Curtis J. Donskey (a1) (a2)
  • In response to commentaries on:

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed